A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation
About
Brief Summary
This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.
- If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive Cancer Center's Office of Regulatory Compliance.
- If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.
Phase
Eligibility
Minimum Age
Maximum Age
Join this Trial
Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
24-000127
Category
Colorectal Cancer
Principal Investigator
Contact
Location
- TRIO-US - Bakersfield
- TRIO-US - Ft. Wayne IN
- TRIO-US - Jonesboro AR
- TRIO-US - Redondo Beach
- TRIO-US - Whittier
- TRIO-US - Wichita KS